- Areas of Interest
- Techniques
- Systems
- Products & Services
- Informatics
- Science & Education
- Company
- Support
Next-generation sequencing (NGS) enables researchers to better understand the biology that drives cancer predisposition and proliferation. These insights can support the development of targeted therapeutics and multi-analyte tumor analysis. NGS also opens the door for discovery of novel methods to monitor cancer treatment and recurrence.
lllumina brings innovation to cancer drug development by offering comprehensive genomic solutions working in collaboration with leading pharmaceutical providers.
As targeted therapies make their way through pharmaceutical pipelines, the need for comprehensive tumor profiling is increasing.
Learn MoreNGS helps drug developers to explore genomic variation. This informs target discovery, validation, and clinical development.
Learn More
Garret Hampton, EVP of Clinical Genomics at Illumina, shares his vision for how genomics might shape the future of oncology.
Almac Diagnostics is using the TruSight Tumor 170 assay for comprehensive high-quality genomic content in one streamlined workflow.
An overview of exciting new fields of immunotherapy research, and how NGS helps to move them forward.
Access resources to explore NGS-based biomarker discovery and profiling.
Regeneron discusses their latest work and overall mission to explore new variations in genomes that can help explain disease.
Chan Zuckerberg Biohub discuss their mission to conduct innovative experiments and new kinds of collaborations in genomics.
Read how Merck Serono uses NGS for cell line stability testing and biosafety monitoring.
All the information you need, from BeadChips to library preparation to sequencer selection and analysis. Select the best tools for your lab.